CA
SPRY icon

Cliff Asness’s ARS Pharmaceuticals SPRY Stock Holding History

Cliff Asness’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
35,676
+9,799
+38% +$84.3K ﹤0.01% 3644
2026
Q1 		$208K Buy
+25,877
New +$248K ﹤0.01% 3589
2025
Q3 		– Sell
-16,132
Closed -$282K – 3579
2025
Q2 		$282K Buy
16,132
+5,016
+45% +$72.4K ﹤0.01% 2899
2025
Q1 		$140K Buy
+11,116
New +$134K ﹤0.01% 2953
2022
Q3 		– Sell
-19,845
Closed -$84K – 2311
2022
Q2 		$84K Buy
19,845
+8,896
+81% +$31K ﹤0.01% 2106
2022
Q1 		$38K Buy
+10,949
New +$47.7K ﹤0.01% 2191

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Cliff Asness's SPRY Position: Q2 2026 in Review

Cliff Asness increased its ARS Pharmaceuticals (SPRY) stake by 38% in Q2 2026, buying an estimated $84.3K and bringing the position to 35,676 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

Cliff Asness first reported a position in SPRY in Q1 2022 and has held it in 6 quarters since. 205 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Cliff Asness held 35,676 shares of ARS Pharmaceuticals worth $286K as of Q2 2026.
  • Cliff Asness bought 9,799 ARS Pharmaceuticals shares in Q2 2026, an estimated $84.3K.
  • ARS Pharmaceuticals made up ﹤0.01% of Cliff Asness's portfolio in Q2 2026, its #3644 holding.
  • Cliff Asness first reported a position in ARS Pharmaceuticals in Q1 2022 and has held it in 6 quarters since.
  • 205 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.